Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 3/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5699154 | 0.82 | TMEM97 (0.32) | HCRTR2HCRTR1TMEM97SIGMAR1 | |
| SCHEMBL346996 | 0.81 | HCRTR1 (0.35) | HCRTR2HCRTR1TMEM97SIGMAR1CA2 | |
| SCHEMBL18302566 | 0.81 | HCRTR1 (0.35) | HCRTR2HCRTR1TMEM97SIGMAR1CA2 | |
| SCHEMBL345860 | 0.81 | HCRTR1 (0.35) | HCRTR2HCRTR1TMEM97SIGMAR1CA2 | |
| SCHEMBL346997 | 0.81 | HCRTR1 (0.35) | HCRTR2HCRTR1TMEM97SIGMAR1CA2 | |
| SCHEMBL25387433 | 0.81 | HCRTR1 (0.35) | HCRTR2HCRTR1TMEM97SIGMAR1CA2 | |
| SCHEMBL8169843 | 0.81 | HCRTR1 (0.35) | HCRTR2HCRTR1TMEM97SIGMAR1CA2 | |
| SCHEMBL18682065 | 0.81 | HCRTR1 (0.35) | HCRTR2HCRTR1TMEM97SIGMAR1CA2 | |
| SCHEMBL19230050 | 0.80 | TRPA1 (0.35) | HCRTR2HCRTR1CA2 | |
| SCHEMBL9332338 | 0.79 | HCRTR1 (0.35) | HCRTR2HCRTR1TMEM97SIGMAR1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230333095-A1 | METHOD FOR DETECTING AN ANALYTE OF INTEREST IN A SAMPLE | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2023-10-19 | — | — | US | disclosed |
| WO-2007070804-A2 | PROCESS FOR PREPARING GEMCITABINE AND ASSOCIATED INTERMEDIATES | CHEMAGIS LTD. (IL) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230333095-A1 | METHOD FOR DETECTING AN ANALYTE OF INTEREST IN A SAMPLE | ENTPD5, KLK3, GUSB | HCRTR2 3015/4885HCRTR1 2773/4885TMEM97 4693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.